In HER2-expressing urothelial cancer, disitamab vedotin plus toripalimab doubled the median progression-free survival, increased the median overall survival, and reduced adverse events as compared with chemotherapy. Full RC48-C016 phase 3 trial results and Research Summary: nej.md/3W76VtS

Bishal Gyawali makes "a case for using superiority design to test de-escalation strategies. This will avoid the limitations of non-inferiority design and make de-escalation strategies more efficient to test."

At 23 years of follow-up, population-based PSA screening of asymptomatic men led to a sustained reduction in prostate cancer mortality, although overdiagnosis remains a concern. Full ERSPC study results: nej.md/42YYsg7 #MedSky #Oncology

3️⃣ Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer (EMBARK trial) nej.md/4h8QpDc 𝗡𝗼𝘁𝗮𝗯𝗹𝗲 𝗵𝗲𝗮𝗱𝗹𝗶𝗻𝗲: Prostate Cancer: Drug Combo Lowers Death Risk by 40% in Aggressive Cases (Newsweek) nej.md/47ztwoa

#ESMO25: Enzalutamide failed to deliver in high-risk localised #ProstateCancer in the ENZARAD trial, but improved OS, with leuprolide, in biochemically recurrent prostate cancer in the final OS analysis of EMBARK. #ESMODailyReporter➡️ https://ow.ly/XCPX50XeO8K Alison Tree

#ESMO25: 177Lu-PSMA-617 with ADT plus ARPI showed PFS benefit in hormone-sensitive #ProstateCancer (#HSPC) but no improvement seen with 177Lu-PSMA-617 vs docetaxel in castration-resistant prostate cancer (#mCRPC) after ARPI. #ESMODailyReporter ➡️ https://ow.ly/2C0e50XeAoj#ESMO25#ProstateCancer

Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study www.thelancet.com/journals/lan...

Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial - The Lancet Oncology www.thelancet.com/journals/lan...

Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....

Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC | New England Journal of Medicine www.nejm.org/doi/full/10....

Great result ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....

#ESMO25: Atezolizumab prolonged DFS in #ctDNA+ muscle-invasive #BladderCancer in the IMvigor011 #ClinicalTrial, providing first evidence in support of minimal residual disease-guided adjuvant #immunotherapy in this setting. #ESMODailyReporter ➡️ https://ow.ly/ythW50XeYRP#ESMO25#ctDNA+

#ESMO25: Use of #ctDNA as a decision-making aid to guide adjuvant chemotherapy may not be ready for prime time in #ColonCancer as two #ClinicalTrials fail to meet their primary endpoints. Read more in the #ESMODailyReporter ➡️ https://ow.ly/OFmM50XeZaZ#ESMO25#ctDNA#ColonCancer#ClinicalTrials#ESMODailyReporter#LiquidBiopsy

#ESMO25: Phase III FORTITUDE-101 #ClinicalTrial reports improved short-term survival with first-in-class FGFR2b inhibitor bemarituzumab added to chemotherapy to treat FGFR2b-overexpressing #Gastric or #GEJCancer. More in the #ESMODailyReporter ➡️ https://ow.ly/C2MU50Xf08l#ESMO25

#ESMO25: First-line ivonescimab, a bispecific antibody targeting PD-1 and VEGF, plus chemotherapy improved progression-free survival vs tislelizumab plus chemotherapy in patients with squamous #NSCLC in the phase III HARMONi-6 trial. #ESMODailyReporter 🔗 https://ow.ly/wl7X50XeA1o#ESMO25#NSCLC

#ESMO25: OS was significantly improved w/ the #ADC disitamab vedotin plus #immunotherapy w/ toripalimab vs chemotherapy in first-line advanced HER2-expressing #UrothelialCarcinoma in the RC48-C016 #ClinicalTrial. #ESMODailyReporter 🔗 https://ow.ly/ZS9V50XeAsN

The combination of enfortumab vedotin (EV) – an antibody–drug conjugate – and pembrolizumab, before and after standard radical cystectomy and pelvic lymph node dissection, may be a potential new standard of care for cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) #esmo25

Five-year results confirm durable DFS benefit and consistent safety profile for adjuvant nivolumab in high-risk MIUC. Post-hoc exploratory ctDNA assessment identified patients at highest risk of recurrence. www.annalsofoncology.org/article/S092...

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study - Annals of Oncology www.annalsofoncology.org/article/S092...

#FLAURA2 analysis of exploratory subgroups shows mOS benefit in: 🧠 brain mets (40.9 v 29.7months) 🥃liver mets (36.6 vs 28months) 🦴bone mets (40.2 va 32.3 months) 🧬ctDNA positive (38.4 vs 32.5 months) Confirms #FLAURA2 approch valid as a SOC in these groups #ESMO25 #LCSM

In high-risk biochemically recurrent prostate cancer, enzalutamide plus leuprolide significantly improved overall survival as compared with leuprolide alone. Enzalutamide monotherapy had no significant benefit for survival. Full EMBARK phase 3 trial results: nej.md/4h8QpDc #ESMO25

In untreated, advanced triple-negative breast cancer, sacituzumab govitecan led to significantly longer progression-free survival than chemotherapy (9.7 months vs. 6.9 months). Full ASCENT-03 phase 3 trial results: nej.md/4ncuUCV #ESMO25

Welcome to #ESMO25: The OncoAlert #LungCancer Faculty, led by Dr.Hidehito Hironouchi 🇯🇵 as well as Dr Biagio Ricciuti 🇺🇸 and Dr. Gil Morgan🇺🇸 , have selected the OncoAlert🚨 TOP 🔟 #LungCancer Abstracts to be presented at #ESMO25 in Berlin 🇩🇪 Picked using a Delphi System to establish our picks. #NSCLC

Useful trial shows value of supportive measures for amivantamab tolerance (doxycycline or minocycline, clindamycin, chlorhexidine (on nails), and ceramide-based moisturizer www.jto.org/article/S155...

At #WCLC25 results of #FLAURA2 showed a 47.5 mo mOS w/ osimertinib+chemo in pts w/ advanced EGFRm+ NSCLC vs 37.6 with osi monotherapy. Benefit seen across subgroups. Longer chemo-free period with combo. #LCSM #LungCancer #NSCLC #oncsky #cansky

The median overall survival of nearly 4 years appears to be the longest benefit ever reported in a global Phase III clinical trial #FLAURA2 in EGFR-mutated advanced lung cancer #WCLC25 #NSCLC #lcsm #medsky #biosky

MARIPOSA phase 3 trial: In advanced non–small-cell lung cancer with EGFR mutations, amivantamab–lazertinib led to longer overall survival than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher. nej.md/4p6j53k #WCLC25 | @iaslc.bsky.social

NADIM ADJUVANT #IASLC #WCLC25

PFS benefit noted with adagrasib

"Baseline PSMA-TTV is prognostic for overall survival and predictive for a beneficial effect on overall survival with the addition of [177Lu]Lu-PSMA-617 to enz as first-line treatment for high-risk metastatic CRPC. By contrast, PSMA SUVmean was not prognostic for PSA progression-free survival or OS"

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....

What does the FDA approval of sunvozertinib mean for patients with EGFR exon 20 insertions? In this week’s #LungCancerConsidered, @stephenvliu.bsky.social talks with Dr. Mariam Alexander and Dr. James Chih-Hsin Yang about the newest EGFR-targeted therapy. 🎧 bit.ly/FDAexon20

DESTINY-Gastric04 trial: Patients with HER2-positive metastatic gastric cancer have limited options after trastuzumab-based treatment. New phase 3 data show longer survival with trastuzumab deruxtecan than with standard second-line chemotherapy. nej.md/46HZ7W3 #MedSky #Oncology

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....

Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST | Journal of Clinical Oncology ascopubs.org/doi/10.1200/...

Beamion LUNG-1 trial: Safe, effective, oral therapies are needed for patients with HER2-mutant non–small-cell lung cancer. Research findings on the oral, irreversible, HER2-selective tyrosine kinase inhibitor zongertinib are summarized in a new Quick Take video. nej.md/3HETKwj #MedSky

In the KEYNOTE-689 phase 3 trial, the addition of neoadjuvant and adjuvant pembrolizumab to standard care improved event-free survival among participants with locally advanced head and neck cancer without affecting surgical outcomes. Full trial results: nej.md/45X0Nuc #MedSky #Oncology

In high-risk cutaneous squamous-cell carcinoma, adjuvant cemiplimab prolonged disease-free survival and reduced recurrence risk as compared with placebo. No new safety concerns with cemiplimab were seen. Full C-POST phase 3 trial results: nej.md/45kvdWR #ASCO25 @ascocancer.bsky.social

DeLLphi-304: Among patients with relapsed small-cell lung cancer after the failure of platinum-based chemotherapy, tarlatamab therapy led to a greater overall and progression-free survival benefit over chemotherapy, with fewer severe adverse events. nej.md/3YWiy8O   #ASCO25

In non–small-cell lung cancer, three cycles of neoadjuvant nivolumab plus chemotherapy improved 5-year overall survival over chemotherapy alone, with variation according to pathological response. Full CheckMate 816 phase 3 trial results: nej.md/4k6Wlxj #ASCO25 @ascocancer.bsky.social

Just presented at #ASCO25: Initial DESTINY-Breast09 results show 1L treatment w/ T-DXd + pertuzumab extends PFS by > 1 year compared w/ SOC THP: dailynews.ascopubs.org/do/destiny-b... #ASCODailyNews #BreastCancer #bcsm @danafarber.bsky.social @danafarbernews.bsky.social

In newly diagnosed myeloma, ASCT showed no benefit over chemotherapy in patients without postinduction measurable residual disease, and tandem ASCT was not more effective than single ASCT in those with postinduction MRD. Full MIDAS trial results: nej.md/4mkaecR   #ASCO25

statistically and clinically significant OS benefit at 5 y for a resectable solid tumor. Pts with pCR with neoadjuvant NIVO + chemo had a ~90% reduction in their risk of death by 5 y compared with those without pCR.

IRONMAN validating the poor prognosis of mHSPC with PSA>0.2 after 6-12 months ADT-ARPI and these patients could be targeted for intensification in future trials. PSA<0.02 at 6-12 m defines the best prognosis and may be of interest for de-intensification strategies. meetings.asco.org/abstracts-pr...

Randomized, double-blind, Phase 3 trial, CAN-2409 significantly reduced the risk of PrCa recurrence or death when added to SoC EBRT+/- ADT. CAN-2409: replication-defective adenovirus encoding the HSV-tk gene that, when combined with valacyclovir (prodrug), results in immunogenic cell death

NIAGARA and ctDNA - ctDNA+ status at pre-RC was associated with non-pCR. - Perioperative Durva provided an EFS benefit to both pts with ctDNA+ and ctDNA− status at baseline - similar trend was observed with DFS based on ctDNA status post-RC meetings.asco.org/abstracts-pr...

Looking forward to #ASCO25. I tried to summarise it, but there’s some really exciting new data. #Bladder new ADCs strategies, pt selection, ctDNA, non-UC subtypes, RT + IO. #Kidney biomarkers, new TKI & HIFi, nccRCC #Prostate new drugs, pt selection, aggressive variants.

What an incredible privilege to sit at the feet of Larry Einhorn as he casts pearls in a continuous shower from the podium before whatever animal I am. What this man does not know about #GermCellCancer #tcsm is probably not worth knowing. Watch his #ASCO25 talk online.

"The DeLLphi-304 trial showed tarlatamab significantly improved OS, PFS, and PROs, with a favorable safety and tolerability profile compared to CTx in pts with SCLC that progressed on or after initial platinum-based CTx, defining a new standard of care for these patients."

Who might benefit from prolonged osi? MRD+ preceded DFS events in most pts with a median lead time of 4.7 mos across both arms. MRD– was maintained for most pts during adj osi tx with the majority of MRD/DFS events occurring after osi tx completion. meetings.asco.org/abstracts-pr...